Chinese Group Develops Melt Curve-PCR Assay for Beta-Thalassemia Genotyping
July 28, 2011
Chinese Group Develops Melt Curve-PCR Assay for Beta-Thalassemia Genotyping
Scientists from China's Xiamen University and a startup company called Xiamen Zeesan Biotech have submitted the test to Chinese regulatory officials for approval as a widespread prenatal diagnostic and screening tool for β-thalassemia.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- China's Zeesan Biotech Developing Portfolio of Melt Curve MDx Assays after SFDA Approves TB Tests
April 25, 2013 / PCR Insider - As Novartis Prenatal Pact Ends, Fluidigm Offers IP to Others, Continues Single-Cell Genomics Push
May 10, 2012 / PCR Insider - Cypriot Group Develops Non-Invasive, Prenatal Down Syndrome Dx; Creates Startup to Market Test
March 10, 2011 / PCR Insider - Sequencing Reveals Entire Fetal Genome in Maternal Plasma; Opens Door for Noninvasive Prenatal Tests
December 14, 2010 / In Sequence - Qiagen, BioBay Open Translational Medicine Center in China
May 24, 2013 / GenomeWeb Daily News